ClinicalTrials.gg
Not yet recruitingNCT07658872Updated Jun 22, 2026

Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma

A Phase 2 interventional study of fruquintinib + sintilimab + SOX and Sinitilimab+SOX in Gastric Adenocarcinoma and Esophagogastric Junction Adenocarcinoma, sponsored by Sichuan University. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Sichuan University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing HMPL-013 in Stomach Neoplasms — 12 open to participants now, 15 under way, 1 of them phase 3. HMPL-013 · Stomach Neoplasms.

Planned enrollment
3rd of 17
120 · median 45
Started
2026
with 2 others
Phase 2
11 of 17
8 open now
Primary completion
2027-05
later than 11 of 14 live
Registered
16th of 17
by date
Lead sponsor
1 of 17
Sichuan University

Among the 17 studies testing HMPL-013 in Stomach Neoplasms, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2026, is one of 11 in phase 2, reaches primary completion later than 11 of the 14 other live ones, and was the 16th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

12 of the 17 studies testing HMPL-013 in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

About HMPL-013

HMPL-013: first FDA approval 2023 (FRUZAQLA), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing HMPL-013 in Stomach Neoplasms, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to evaluate whether perioperative fruquintinib combined with sintilimab and SOX is effective in treating locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The study will also assess the safety profile of this treatment regimen.

Primary Objective:

To determine whether perioperative fruquintinib combined with sintilimab and SOX improves the pathological complete response (pCR) rate compared with sintilimab plus SOX in patients with locally advanced gastric or GEJ adenocarcinoma.

Study Design:

Participants will be randomly assigned to receive either fruquintinib combined with sintilimab and SOX or sintilimab plus SOX to evaluate the potential added benefit of fruquintinib in this setting.

Participation Details:

Participants will receive the assigned treatment (fruquintinib combined with sintilimab and SOX or sintilimab plus SOX) every 21 days for approximately 3 months.

They will visit the clinic once every 3 weeks for evaluations, laboratory tests, and monitoring.

Participants will be asked to keep a daily diary to record any symptoms or side effects experienced during the study.

03

Conditions studied

  • Gastric Adenocarcinoma
  • Esophagogastric Junction Adenocarcinoma

Browse trials for

Keywords

  • Gastric Cancer
  • neoadjuvant treatment
  • Fruquintinib
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years.
  2. confirmed gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
  3. (ECOG) performance status 0-1.
  4. Clinically staged as T3-4a N0-3M0 by computed tomography (CT) or magnetic resonance imaging (MRI).
  5. Considered eligible for curative resection.
  6. No prior antitumor therapy for the current disease.
  7. Adequate organ function, including hepatic, renal, and bone marrow function, as per prespecified laboratory criteria.
  8. Expected survival of ≥6 months.

Exclusion criteria

Exclusion Criteria:

  1. Known mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) tumor.
  2. Uncontrolled hypertension, defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥ 90 mmHg despite optimized antihypertensive therapy, or hypertension complicated by acute events (e.g., hypertensive crisis, hypertensive encephalopathy) that cannot be stably controlled.
  3. Tumor lesions with a bleeding tendency, including but not limited to: active ulcerative tumor lesions, hematemesis within 2 months prior to , high risk of major gastrointestinal bleeding as determined by the investigator.
  4. History of thromboembolic or arterial/venous vascular events within 6 months prior to enrollment, such as cerebrovascular events (including ), deep vein thrombosis, or pulmonary embolism.
  5. Gastrointestinal perforation or gastrointestinal obstruction within 6 months prior to enrollment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Fruquintinib + Sintilimab + SOX

    Drug: fruquintinib + sintilimab + SOX

  • Active comparator
    Sintilimab + SOX

    Drug: Sinitilimab+SOX

Interventions

  • Drugfruquintinib + sintilimab + SOX

    Drug pages: HMPL-013Studies of HMPL-013HMPL-013 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · SintilimabStudies of SintilimabSintilimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Fruquintinib, 4mg po d1-14 q3w, four 3-week cycles were administered; S-1 (administered orally twice daily on days 1-14 of each 21-day cycle, with the daily dose determined by body surface area: \<1.25 m², 80 mg/day; ≥1.25 to \<1.5 m², 100 mg/day; ≥1.5 m², 120 mg/day), four 3-week cycles were administered. Oxaliplatin (130 mg/m², administered intravenously on day 1), four 3-week cycles were administered.

  • DrugSinitilimab+SOX

    S-1 (administered orally twice daily on days 1-14 of each 21-day cycle, with the daily dose determined by body surface area: \<1.25 m², 80 mg/day; ≥1.25 to \<1.5 m², 100 mg/day; ≥1.5 m², 120 mg/day), four 3-week cycles were administered. Oxaliplatin (130 mg/m², administered intravenously on day 1), four 3-week cycles were administered.

06

What researchers measure

Primary outcomes

  1. Total pathological complete response (pCR)

    Total pathological complete response (pCR; ypT0) assessed by investigators, defined as the complete absence of tumor cells in the primary tumor on pathological examination.

    Time frame: Perioperative

Secondary outcomes

  1. Event-free survival (EFS)

    Event-free survival (EFS), defined as the time from randomization to the first occurrence of relapse, metastasis, or death from any cause;

    Time frame: Through study completion, an average of 2 years

  2. TRAEs

    Treatment-related adverse events (TRAEs) with potential immunologic etiology were categorized and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) (Version 5.0)

    Time frame: Through study completion,an average of 2 years

  3. major pathologic response(MPR)

    major pathologic response(MPR) defined as ≤10% residual viable tumor cells in the resected primary tumor specimen after neoadjuvant therapy;

    Time frame: Perioperative

  4. R0 resection

    R0 resection defined as microscopically margin-negative resection

    Time frame: Perioperative

  5. overall survival (OS)

    OS defined as the time from randomization to death from any cause;

    Time frame: Through study completion,an average of 2 years

  6. Expression of Predictive Biomarkers Associated With Treatment Response

    Predictive biomarkers including PD-L1 expression, Epstein-Barr virus status, tumor mutational burden, and immune-related biomarkers will be analyzed for association with pathological and radiographic treatment response.

    Time frame: Baseline through study completion, an average of 2 years

  7. Change in Quality of Life Assessed by EORTC QLQ-C30

    Quality of life was assessed using the EORTC QLQ-C30 questionnaires, administered at three time points: within one week before initiation of neoadjuvant therapy, within one week before the fourth neoadjuvant therapy cycle, and at 30 days postoperatively (±3 days)

    Time frame: Through study completion, an average of 2 years

  8. disease-free survival (DFS)

    DFS defined as the time from the post-surgery baseline scan to the first occurrence of relapse, metastasis, or death from any cause

    Time frame: From date of post-surgery until the date of first occurrence of relapse, metastasis, or date of death from any cause, whichever came first, assessed up to 100 months

  9. Change in Quality of Life Assessed by EORTC QLQ-STO22

    Quality of life was assessed using the EORTC QLQ-STO22 questionnaires, administered at three time points: within one week before initiation of neoadjuvant therapy, within one week before the fourth neoadjuvant therapy cycle, and at 30 days postoperatively (±3 days).

    Time frame: Through study completion, an average of 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Individual Participant Data (IPD) may not be shared due to privacy and confidentiality concerns, legal or ethical restrictions, limitations in data sharing agreements or consent, intellectual property rights, commercial interests, or because of technical and resource constraints related to data anonymization and sharing.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for May 2027, 11 months later.

Of 296 non-industry phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 76. This study's planned 11 months is below that.

Counting every sponsor, half of 361 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2026
First posted
Jun 22, 2026
StartEst.
Jun 15, 2026
Primary completionEst.
May 19, 2027
CompletionEst.
Apr 6, 2028
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07658872
Lead sponsor
Sichuan University
Responsible party
Bo Zhang, MD (Chief Physician, Sichuan University) — Principal investigator
First posted
Jun 22, 2026
Start date
Jun 15, 2026 (estimated)
Primary completion
May 19, 2027 (estimated)
Completion
Apr 6, 2028 (estimated)
Last update
Jun 22, 2026

Study contacts

Hongfeng Gou, PhD
Contact
gouhongfeng1977@wchscu.cn
+86-18980602292
Wen Nie, Ph.D
Contact
wennie1228@gmail.com
+86-02885423297
Hongfeng Gou, Ph.D
principal investigator · Gastric Cancer Center, West China Hospital, Sichuan University, 37 Guoxue Alley, Chengdu 610041, Sichuan, China.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HMPL-013 · Sintilimab

Start the discussion